Cytomegalovirus (HHV-5) Infections - Pipeline Review, H1 2018

  • ID: 4531951
  • Report
  • 170 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • AIMM Therapeutics BV
  • Biotest AG
  • GlaxoSmithKline Plc
  • Merck & Co Inc
  • Phoenix Biotechnology Inc
  • Trellis Bioscience Inc
  • MORE
Cytomegalovirus (HHV-5) Infections - Pipeline Review, H1 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Cytomegalovirus (HHV-5) Infections - Pipeline Review, H1 2018, provides an overview of the Cytomegalovirus (HHV-5) Infections (Infectious Disease) pipeline landscape.

Cytomegalovirus (CMV) is a contagious infection of the caused by the member of the herpes virus family. CMV is spread through saliva or urine. Symptoms include fever, pneumonia, weight loss, hearing, neurological and developmental problems. The predisposing factors are exposure direct contact with infected surface or organism, weakened immune system and congenital factors. It may be diagnosed by blood or urine tests. The condition may be controlled by the use of medication such as anti-viral and may be prevented by lifestyle modification.

Report Highlights:

This latest pipeline guide Cytomegalovirus (HHV-5) Infections - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Cytomegalovirus (HHV-5) Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Cytomegalovirus (HHV-5) Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Cytomegalovirus (HHV-5) Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 10, 9, 1, 20, 10 and 2 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Phase 0, Preclinical and Discovery stages comprises 1, 6, 7, 1, 5 and 3 molecules, respectively.

Cytomegalovirus (HHV-5) Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Cytomegalovirus (HHV-5) Infections (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Cytomegalovirus (HHV-5) Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Cytomegalovirus (HHV-5) Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Cytomegalovirus (HHV-5) Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Cytomegalovirus (HHV-5) Infections (Infectious Disease)
Reasons for Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Cytomegalovirus (HHV-5) Infections (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Cytomegalovirus (HHV-5) Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AIMM Therapeutics BV
  • Biotest AG
  • GlaxoSmithKline Plc
  • Merck & Co Inc
  • Phoenix Biotechnology Inc
  • Trellis Bioscience Inc
  • MORE
Introduction

Cytomegalovirus (HHV-5) Infections - Overview

Cytomegalovirus (HHV-5) Infections - Therapeutics Development

Cytomegalovirus (HHV-5) Infections - Therapeutics Assessment

Cytomegalovirus (HHV-5) Infections - Companies Involved in Therapeutics Development

Cytomegalovirus (HHV-5) Infections - Drug Profiles

Cytomegalovirus (HHV-5) Infections - Dormant Projects

Cytomegalovirus (HHV-5) Infections - Discontinued Products

Cytomegalovirus (HHV-5) Infections - Product Development Milestones

Appendix

List of Tables

Number of Products under Development for Cytomegalovirus (HHV-5) Infections, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018 (Contd..1), H1 2018

Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Products under Development by Companies, H1 2018 (Contd..2), H1 2018

Products under Development by Companies, H1 2018 (Contd..3), H1 2018

Products under Development by Universities/Institutes, H1 2018

Products under Development by Universities/Institutes, H1 2018 (Contd..1), H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Cytomegalovirus (HHV-5) Infections - Pipeline by AIMM Therapeutics BV, H1 2018

Cytomegalovirus (HHV-5) Infections - Pipeline by AlfaSigma SpA, H1 2018

Cytomegalovirus (HHV-5) Infections - Pipeline by Atara Biotherapeutics Inc, H1 2018

Cytomegalovirus (HHV-5) Infections - Pipeline by AvidBiotics Corp, H1 2018

Cytomegalovirus (HHV-5) Infections - Pipeline by Biotest AG, H1 2018

Cytomegalovirus (HHV-5) Infections - Pipeline by Chimerix Inc, H1 2018

Cytomegalovirus (HHV-5) Infections - Pipeline by China Biologic Products Inc, H1 2018

Cytomegalovirus (HHV-5) Infections - Pipeline by CyTuVax BV, H1 2018

Cytomegalovirus (HHV-5) Infections - Pipeline by Fate Therapeutics Inc, H1 2018

Cytomegalovirus (HHV-5) Infections - Pipeline by GlaxoSmithKline Plc, H1 2018

Cytomegalovirus (HHV-5) Infections - Pipeline by Hookipa Biotech AG, H1 2018

Cytomegalovirus (HHV-5) Infections - Pipeline by Kadmon Corp LLC, H1 2018

Cytomegalovirus (HHV-5) Infections - Pipeline by Laboratoires Thea SA, H1 2018

Cytomegalovirus (HHV-5) Infections - Pipeline by Merck & Co Inc, H1 2018

Cytomegalovirus (HHV-5) Infections - Pipeline by Microbiotix Inc, H1 2018

Cytomegalovirus (HHV-5) Infections - Pipeline by Moderna Therapeutics Inc, H1 2018

Cytomegalovirus (HHV-5) Infections - Pipeline by Novartis AG, H1 2018

Cytomegalovirus (HHV-5) Infections - Pipeline by Phoenix Biotechnology Inc, H1 2018

Cytomegalovirus (HHV-5) Infections - Pipeline by Qurient Co Ltd, H1 2018

Cytomegalovirus (HHV-5) Infections - Pipeline by Shire Plc, H1 2018

Cytomegalovirus (HHV-5) Infections - Pipeline by Themis Bioscience GmbH, H1 2018

Cytomegalovirus (HHV-5) Infections - Pipeline by Trellis Bioscience Inc, H1 2018

Cytomegalovirus (HHV-5) Infections - Pipeline by Vakzine Projekt Management GmbH, H1 2018

Cytomegalovirus (HHV-5) Infections - Pipeline by VBI Vaccines Inc, H1 2018

Cytomegalovirus (HHV-5) Infections - Pipeline by Vectorite Biomedical Inc, H1 2018

Cytomegalovirus (HHV-5) Infections - Pipeline by Vical Inc, H1 2018

Cytomegalovirus (HHV-5) Infections - Dormant Projects, H1 2018

Cytomegalovirus (HHV-5) Infections - Dormant Projects, H1 2018 (Contd..1), H1 2018

Cytomegalovirus (HHV-5) Infections - Dormant Projects, H1 2018 (Contd..2), H1 2018

Cytomegalovirus (HHV-5) Infections - Dormant Projects, H1 2018 (Contd..3), H1 2018

Cytomegalovirus (HHV-5) Infections - Discontinued Products, H1 2018

List of Figures

Number of Products under Development for Cytomegalovirus (HHV-5) Infections, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Number of Products by Top 10 Targets, H1 2018

Number of Products by Stage and Top 10 Targets, H1 2018

Number of Products by Top 10 Mechanism of Actions, H1 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Top 10 Molecule Types, H1 2018

Number of Products by Stage and Top 10 Molecule Types, H1 2018
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • AIMM Therapeutics BV
  • AlfaSigma SpA
  • Atara Biotherapeutics Inc
  • AvidBiotics Corp
  • Biotest AG
  • Chimerix Inc
  • China Biologic Products Inc
  • CyTuVax BV
  • Fate Therapeutics Inc
  • GlaxoSmithKline Plc
  • Hookipa Biotech AG
  • Kadmon Corp LLC
  • Laboratoires Thea SA
  • Merck & Co Inc
  • Microbiotix Inc
  • Moderna Therapeutics Inc
  • Novartis AG
  • Phoenix Biotechnology Inc
  • Qurient Co Ltd
  • Shire Plc
  • Themis Bioscience GmbH
  • Trellis Bioscience Inc
  • Vakzine Projekt Management GmbH
  • VBI Vaccines Inc
  • Vectorite Biomedical Inc
  • Vical Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll